R. Khanal

Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes

F. Aziz, S. Dutta, R. Khanal, 2009 .

Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.

C. Denlinger, R. Khanal, Anthony Stack, 2020, Clinical colorectal cancer.

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

R. Houot, M. Kersten, I. Flinn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

S. de Vos, D. Maloney, I. Yakoub-Agha, 2021, Blood.

Afatinib and lung cancer

N. Sharma, P. Jain, R. Khanal, 2014, Expert review of anticancer therapy.

Invasion of Fall armyworm [Spodoptera frugiperda (JE Smith, 1797) (Lepidoptera: Noctuidae)] (JE Smith ,1797) (Lepidoptera: Noctuidanead) Management Strategies in Maize Fields of Nepal

I. Gautam, R. Khanal, Neha Sah, 2022, Turkish Journal of Agriculture - Food Science and Technology.

Fosaprepitant as a risk factor for ifosfamide induced encephalopathy: A single institution experience.

Genevieve Hayes, R. Khanal, Ridhi Gupta, 2016 .

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

S. de Vos, C. Jacobson, S. Neelapu, 2023, Blood.